Kadimastem Ltd

Equities

KDST

IL0011284614

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:05 2024-05-01 am EDT			5-day change	1st Jan Change
512.9 ^ILa	+4.14%		+5.06%	-13.51%

Mar. 28	Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	MT

Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 01:38 pm EDT

Kadimastem Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was ILS 12.01 million compared to ILS 22.72 million a year ago. Basic loss per share from continuing operations was ILS 2.8. Diluted loss per share from continuing operations was ILS 2.8.

Latest news about Kadimastem Ltd

Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	Feb. 28	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	Feb. 27	CI
Kadimastem Plans Listing on Nasdaq Through Merger	Feb. 18	CI
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	Nov. 07	CI
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor	23-10-15	CI
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Kadimastem Ltd announced that it expects to receive ILS 3.53 million in funding	17-07-06	CI
Kadimastem to Launch Clinical Trial in ALS Patients Upon Approval from the Hadassah Hospital IRB	17-06-22	CI
Kadimastem Receives Approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the Phase 1/2A Clinical Trial in Als Patients	17-06-21	CI
Kadimastem Ltd announced that it expects to receive ILS 2.13 million in funding	17-06-06	CI
Kadimastem Ltd. Announces Resignation of Eynat Tsafrir, Independent Director	17-06-04	CI
Kadimastem Ltd announced that it expects to receive ILS 1 million in funding	17-03-27	CI
Kadimastem Announces Granting a Patent in the US for Treatment of Neurodegenerative Diseases	17-03-16	CI
Kadimastem Ltd. announced that it expects to receive ILS 2.7 million in funding	17-01-22	CI
Kadimastem Ltd. announced that it expects to receive ILS 2.5 million in funding	16-11-07	CI

Chart Kadimastem Ltd

Duration

Period

More charts

Company Profile

Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KADIMASTEM LTD	-13.51%	5.53M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs